Objective To evaluate clinical effects of dendritic cells ( DC ) combined with cytokine induced killer cells ( CIK ) therapy for advanced colorectal cancer. Methods Forty advanced colorectal cancer patients were randomly divided into treatment group and control group. The treatment group was given immunotherapy combined with chemotherapy. The treatment group was also given DC and CIK at an interval of 10 ~ 14 days after chemotherapy. The control group was only given chemotherapy. T lymphocyte subtypes in peripheral blood of two groups ( CD3 + , CD4 + , CD8 + , CD4 + /CD8 + ) were analyzed before and after treatment. Performance Status ( KPS ), clinical effects and side effects were observed. Results The level of CD3 + showed significant difference before and after treatment in the treatment group ( P = 0. 001 ), while the levels of CD4 + , CD8 + , CD4 + / CD8 + showed no significant difference before and after treatment ( P > 0. 05 ) . The levels of CD3 + , CD4 + , CD8 + , CD4 + / CD8 + showed no significant difference before and after treatment in the control group ( P > 0. 05 ) . The effective rate in treatment group and control group was 45% and 35% respectively ( P > 0. 05 ); The effective rate of KPS in treatment group and control group was 80% and 60% respectively, the difference was statistically significant ( P < 0. 05 ) . Conclusion DC combined with CIK therapy can improve T lymphocyte subtypes in peripheral blood of advanced colorectal cancer patients, and it can also improve thelife quality of patients.%目的 探讨树突细胞(DC)联合细胞因子诱导的杀伤细胞(CIK)治疗晚期结直肠癌患者的临床疗效.方法 将40例临床确诊的晚期结直肠癌患者随机分为两组,观察组给予免疫治疗联合化疗,对照组仅给予化疗.观察两组患者治疗前后细胞免疫指标(CD3+、CD4+、CD8+细胞比例及CD4+/CD8+)变化、卡氏评分(Karnofsky,KPS评分)和疗效,并观察其不良反应.结果 观察组患者治疗后CD3+细胞的比例较治疗前显著增加,差异有统计学意义(P=0.001);而CD4+、CD8+细胞的比例及CD4+/CD8+治疗前后比较,差异无统计学意义(P＞0.05).对照组免疫学指标(CD3+、CD4+、CD8+细胞的比例及CD4+/CD8+)治疗前后比较,差异均无统计学意义(P＞0.05).观察组患者治疗后有效率为45%,对照组有效率为35%,两组比较差异无统计学意义(P＞0.05);观察组KPS评分总提高率为80%,对照组为60%,两组比较差异有统计学意义(P＜0.05).结论 DC联合CIK治疗可明显改善晚期结直肠癌患者外周血淋巴细胞亚群水平,能提高患者的生活质量.
展开▼
